Commission intensifies 'no-deal' Brexit customs preparedness

19 February 2019

In another move that the European Union is preparing for the UK to leave the bloc on March 29 with no exit agreement, the European Commission on Monday stepped up its “no-deal” outreach to EU businesses in the area of customs and indirect taxation such as value-added tax (VAT), given the risk that the UK may leave the EU without a deal.

The outreach campaign is part of the Commission's ongoing efforts to prepare for the UK's exit of the European Union without a deal, in line with the European Council (Article 50) conclusions of December 2018, calling for intensified preparedness work for all scenarios.

This campaign should help to inform businesses that want to continue trading with the UK after 30 March on what they need to do to ensure as smooth a transition as possible. Preparing for the UK becoming a non-EU country is of paramount importance if significant disruption for EU business is to be avoided.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK